Patient-Focused Drug Development meetings are where the FDA builds its formal record of the patient experience, and this one turns to nonhealing chronic wounds. The hybrid public meeting — , 10:00 a.m. to 4:30 p.m. ET — gathers patient perspectives on living with chronic wounds, current treatment approaches, and what matters when selecting one.
Date, venue and registration
- Meeting: 25 August 2026, 10:00 a.m.–4:30 p.m. ET
- Venue: FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room, Silver Spring, MD
- Webcast: live webcast, registration via the FDA event page
- Registration: free for in-person and virtual attendance
- Docket: FDA-2026-N-5057; comments due 26 October 2026
- Organizer: US Food and Drug Administration
Why this meeting matters
The transcript and docket from a PFDD meeting become reference material for the FDA's benefit-risk assessments in that disease area, and sponsors developing wound-care therapeutics cite them in regulatory strategy. If your pipeline touches chronic wounds — drugs, biologics or combination products — the perspectives recorded here will shape the review environment those products meet.
Who should attend
The meeting exists to hear from patients and caregivers, but the audience that acts on it is professional: regulatory affairs and clinical development teams in wound care, medical affairs staff building patient-experience data programs, and patient-advocacy liaisons. The webcast makes following the record straightforward; presenting a perspective requires registering through the FDA event page.
Tracking the FDA's autumn calendar? The agency's public hearing on psychedelic drugs follows on 14 September, and the full events directory lists everything we have verified.
Frequently asked questions
When is the FDA's PFDD meeting on nonhealing chronic wounds?
25 August 2026, from 10:00 a.m. to 4:30 p.m. Eastern Time. The FDA announced the date in its Federal Register notice of 29 May 2026 (Docket No. FDA-2026-N-5057).
Can I attend the chronic wounds PFDD meeting virtually?
Yes. The meeting is hybrid: in person in the Building 31 Great Room at the FDA's White Oak campus, and via a live webcast. Registration is free for both formats.
What is a patient-focused drug development meeting?
PFDD meetings are the FDA's structured way of hearing directly from patients: how a condition affects daily life, what current treatments do and don't achieve, and what patients would want from new therapies. The record informs the agency's benefit-risk thinking for products in that disease area.
Sources & further reading
- Federal Register. Patient-Focused Drug Development for Nonhealing Chronic Wounds; Public Meeting; Request for Comments — 29 May 2026. federalregister.gov
Event details are published by the organizer and can change. Confirm the date, format and registration with the FDA before making plans. Last verified 16 July 2026.
